CONDITION AND RESULTS OF OPERATIONS The following discussion analysis financial condition AbbVie Inc AbbVie company March 31 2017 December 31 2016 results operations three months ended March 31 2017 2016 This commentary read conjunction condensed consolidated financial statements accompanying notes appearing Item 1 Financial Statements Supplementary Data EXECUTIVE OVERVIEWCompany OverviewAbbVie global research-based biopharmaceutical company formed 2013 following separation Abbott Laboratories Abbott AbbVie mission use expertise dedicated people unique approach innovation develop market advanced therapies address world complex serious diseases AbbVie products focused treating conditions chronic autoimmune diseases rheumatology gastroenterology dermatology oncology including blood cancers virology including hepatitis C HCV human immunodeficiency virus HIV neurological disorders Parkinson disease multiple sclerosis metabolic diseases including thyroid disease complications associated cystic fibrosis well serious health conditions AbbVie also pipeline promising new medicines across important medical specialties immunology virology oncology neurology additional targeted investment cystic fibrosis women health.AbbVie products generally sold worldwide directly wholesalers distributors government agencies health care facilities specialty pharmacies independent retailers AbbVie-owned distribution centers public warehouses In United States AbbVie distributes pharmaceutical products principally independent wholesale distributors sales directly pharmacies patients Outside United States sales made either directly customers distributors depending market served Certain products co-marketed co-promoted companies AbbVie approximately 29,000 employees AbbVie operates one business segment pharmaceutical products.2017 Strategic ObjectivesAbbVie mission innovation-driven patient-focused specialty biopharmaceutical company capable achieving top-tier financial performance outstanding execution consistent stream innovative new medicines AbbVie intends continue advance mission number ways including growing revenues continued strong performance existing portfolio on-market products including flagship brands HUMIRA IMBRUVICA well growth pipeline products ii expanding operating margins iii continued investment pipeline support opportunities immunology oncology virology neurology well continued investment key on-market products iv augmentation pipeline concerted focus strategic licensing acquisition partnering activity focus identifying compelling programs fit AbbVie strategic criteria v returning cash shareholders via dividends share repurchases In addition AbbVie anticipates several regulatory submissions key data readouts key clinical trials next twelve months Financial ResultsThe company's financial performance three months ended March 31 2017 included delivering worldwide net revenues 6.5 billion operating earnings 2.4 billion diluted earnings per share 1.06 Worldwide net revenues grew 10 constant currency basis driven primarily continued strength HUMIRA revenue growth related IMBRUVICA revenue growth key products including Creon Duodopa These increases partially offset primarily decline net revenues VIEKIRA.Diluted earnings per share 1.06 three months ended March 31 2017 included following after-tax costs 203 million related amortization intangible assets ii 84 million change fair value contingent consideration liabilities iii milestone payments 28 million iv acquisition related costs 25 million Additionally financial results three months ended March 31 2017 reflected continued added funding support AbbVie emerging mid late-stage pipeline assets continued investment AbbVie growth brands.The company generated cash flows operations 2.1 billion three months ended March 31 2017 AbbVie utilized continue enhance pipeline licensing collaboration activities pay cash dividends stockholders 1.0 2017 Form 10-Q 25billion repurchase approximately 7.8 million shares 500 million open market In February 2017 AbbVie board directors declared quarterly cash dividend 0.64 per share common stock payable May 2017.In addition financial results AbbVie continued advance augment pipeline described heading Research Development Research DevelopmentResearch innovation cornerstones AbbVie business global biopharmaceutical company AbbVie long-term success depends great extent ability continue discover develop innovative pharmaceutical products acquire collaborate compounds currently development biotechnology pharmaceutical companies.AbbVie pipeline currently includes 50 compounds indications clinical development individually collaboration license agreements focused important medical specialties immunology oncology virology neurology along targeted investments cystic fibrosis women health Of programs 30 mid late-stage development The following sections summarize transitions significant programs Phase 2 development Phase 3 development well developments significant Phase 3 registration programs AbbVie expects multiple Phase 2 programs transition Phase 3 programs next twelve months.Significant Programs DevelopmentsOncologyIMBRUVICA In January 2017 AbbVie announced FDA approved IMBRUVICA treatment patients relapsed/refractory marginal zone lymphoma MZL require systemic therapy received least one prior anti-CD20-based therapy This indication approved accelerated approval based overall response rate ORR continued approval may contingent upon verification description clinical benefit confirmatory trial MZL slow-growing form non-Hodgkin's lymphoma This marks seventh FDA approval fifth disease indication IMBRUVICA since medication's initial approval 2013 In April 2017 AbbVie announced FDA accepted supplemental New Drug Application sNDA IMBRUVICA chronic graft-versus-host-disease cGVHD failure one lines systemic therapy cGVHD severe potentially life-threatening consequence stem cell bone marrow transplant If approved FDA IMBRUVICA first therapy specifically approved treat condition.Venetoclax AbbVie recently initiated Phase 3 clinical trial study safety efficacy venetoclax combination azacitidine untreated treatment-na elderly subjects acute myeloid leukemia ineligible standard induction therapy high-dose chemotherapy Rova-T AbbVie recently initiated Phase 3 clinical trial evaluate efficacy Rova-T maintenance therapy following first-line platinum based chemotherapy participants extensive stage small cell lung cancer.Veliparib In April 2017 AbbVie announced two Phase 3 studies evaluating veliparib investigational oral poly adenosine diphosphate-ribose polymerase PARP inhibitor combination chemotherapy meet primary endpoints The studies evaluated veliparib combination carboplatin paclitaxel patients squamous non-small cell lung cancer NSCLC triple negative breast cancer TNBC Ongoing Phase 3 studies include non-squamous non-small cell lung cancer BRCA1/2 breast cancer ovarian cancer.2017 Form 10-Q 26Virology/Liver Disease In January 2017 AbbVie announced marketing authorization application MAA validated accelerated assessment European Medicines Agency EMA company's investigational pan-genotypic regimen glecaprevir/pibrentasvir G/P treatment major chronic HCV genotypes G/P also intended address needs patients specific treatment challenges including severe chronic kidney disease CKD cured previous direct-acting antiviral DAA treatment In February 2017 AbbVie announced FDA accepted New Drug Application NDA granted priority review company's investigational pan-genotypic regimen G/P treatment major chronic HCV genotypes In February 2017 AbbVie announced Committee Medicinal Products Human Use CHMP granted positive opinion shorter eight-week treatment VIEKIRAX ombitasvir/paritaprevir/ritonavir tablets EXVIERA dasabuvir tablets option previously untreated adult patients genotype 1b chronic HCV minimal moderate fibrosis For comprehensive discussion AbbVie products pipeline see company Annual Report Form 10-K year ended December 31 2016 RESULTS OF OPERATIONSNet Revenues The comparisons presented constant currency rates reflect comparative local currency net revenues prior year foreign exchange rates This measure provides information change net revenues assuming foreign currency exchange rates changed prior current periods AbbVie believes non-GAAP measure change net revenues constant currency rates used conjunction GAAP measure change net revenues actual currency rates may provide complete understanding company operations facilitate analysis company results operations particularly evaluating performance one period another Three months endedMarch 31 Percent change At actual currency rates At constant currency rates(dollars millions 20172016 United States $4,052 $3,494 15.9 15.9%International 2,486 2,464 0.9 1.8%Net revenues $6,538 $5,958 9.7 10.1%2017 Form 10-Q 27The following table details AbbVie worldwide net revenues Three months endedMarch 31 Percent change At actual currency rates At constant currency rates(dollars millions 2017 2016 HUMIRA United States $2,696 $2,195 22.8 22.8 %International 1,422 1,382 2.9 4.6 %Total $4,118 $3,577 15.1 15.8 %IMBRUVICA United States $457 $325 40.7 40.7 %Collaboration revenues 94 56 68.0 68.0 %Total $551 $381 44.7 44.7 %VIEKIRA United States $38 $125 (69.6 69.6 International 225 289 (21.9 20.8 Total $263 $414 (36.3 35.5 Lupron United States $155 $151 1.9 1.9 %International 39 39 1.2 0.2 Total $194 $190 1.7 1.4 %Creon United States $185 $150 22.8 22.8 %Synagis International $300 $319 (5.9 8.2 Synthroid United States $192 $182 5.7 5.7 %AndroGel United States $136 $156 (12.8 12.8 Kaletra United States $19 $33 (41.8 41.8 International 96 100 (4.4 6.4 Total $115 $133 (13.6 15.1 Sevoflurane United States $18 $17 0.7 0.7 %International 89 94 (4.9 3.0 Total $107 $111 (4.0 2.4 Duodopa United States $14 $7 84.6 84.6 %International 66 61 8.9 12.0 %Total $80 $68 17.0 19.8 %All $297 $277 7.7 8.5 %Total net revenues $6,538 $5,958 9.7 10.1 %The following discussion analysis AbbVie net revenues product presented constant currency basis.Global HUMIRA sales increased 16 three months ended March 31 2017 primarily result market growth across therapeutic categories geographies favorable pricing certain geographies In United States HUMIRA sales increased 23 three months ended March 31 2017 driven prescription volume favorable pricing market growth across indications Internationally HUMIRA sales increased 5 three months ended March 31 2017 driven primarily market growth AbbVie continues pursue strategies help differentiate HUMIRA competing products add sustainability future growth HUMIRA.2017 Form 10-Q 28Net revenues IMBRUVICA represent product revenues United States collaboration revenues outside United States related AbbVie 50 share IMBRUVICA profit Global IMBRUVICA sales increased 45 three months ended March 31 2017 result continued penetration IMBRUVICA first-line treatment patients chronic lymphocytic leukemia CLL well favorable pricing.Global VIEKIRA sales decreased 36 three months ended March 31 2017 result lower market share primarily United States market contraction price erosion In United States sales decreased 70 three months ended March 31 2017 primarily due contraction overall market lower market share International revenues decreased 21 three months ended March 31 2017 primarily due market declines price erosion certain geographies.Net revenues Creon increased 23 three months ended March 31 2017 driven primarily continued market growth higher market share Creon maintains market leadership pancreatic enzyme market.Synagis seasonal product majority sales occurring first fourth quarters Synagis revenues three months ended March 31 2017 decreased 8 primarily due lower volume certain geographies.Net revenues Duodopa increased 20 three months ended March 31 2017 primarily result market penetration geographic expansion Duopa approved United States January 2015 AbbVie expects net revenues Duopa United States continue gradually increase product gains acceptance marketplace Gross Margin Three months endedMarch 31 dollars millions 2017 2016 changeGross margin $4,922 $4,589 7%as net revenues 75 77 Gross margin percentage net revenues decreased three months ended March 31 2017 compared prior year period primarily due impact higher intangible asset amortization impact IMBRUVICA profit sharing arrangement unfavorable foreign exchange rates These reductions partially offset favorable impact product mix across portfolio.Selling General Administrative Three months endedMarch 31 dollars millions)20172016 changeSelling general administrative 1,368 $1,355 1%as net revenues 21 23 SG&A expenses percentage net revenues decreased three months ended March 31 2017 compared prior year period due continued leverage revenue growth.2017 Form 10-Q 29Research Development Acquired In-Process Research Development Three months endedMarch 31 dollars millions 2017 2016 changeResearch development $1,135 $946 20 %as net revenues 17 16 Acquired in-process research development 10 (100 Research Development R&D expenses three months ended March 31 2017 increased compared prior year period principally due increased funding support company emerging mid late-stage pipeline assets impact post-acquisition R&D expenses Stemcentrx BI compounds.Other Non-Operating Expenses Three months endedMarch 31 millions 2017 2016Interest expense $273 $215Interest income (26 15)Interest expense net $247 $200 Net foreign exchange loss 13 $302Other expense net 73 Interest expense net three months ended March 31 2017 increased prior year due May 2016 issuance 7.8 billion aggregate principal amount senior notes issued primarily finance acquisition Stemcentrx repay outstanding term loan Net foreign exchange loss three months ended March 31 2016 included losses totaling 298 million related devaluation AbbVie net monetary assets denominated Venezuelan bolivar See Note 8 Condensed Consolidated Financial Statements additional information regarding Venezuelan devaluation.Other expense net three months ended March 31 2017 included charge 85 million related change fair value BI Stemcentrx contingent consideration liabilities The fair value contingent consideration liabilities impacted passage time multiple inputs including probability success achieving regulatory/commercial milestones discount rates market-based factors For three months ended March 31 2017 change fair value represented mainly passage time See Note 4 Condensed Consolidated Financial Statements additional information regarding acquisitions Stemcentrx BI compounds.Income Tax ExpenseThe effective tax rate 18 three months ended March 31 2017 24 three months ended March 31 2016 The effective tax rate period differed statutory tax rate principally due benefit foreign operations reflects impact lower income tax rates locations outside United States tax exemptions incentives Puerto Rico foreign tax jurisdictions business development activities together cost repatriation decisions The decrease effective tax rate three months ended March 31 2017 prior year principally due changes jurisdictional mix earnings well certain discrete factors events including collaborations impact prior year non-deductible devaluation loss related Venezuela impact adoption ASU No 2016-09 changed accounting treatment excess tax benefits associated stock-based awards See Note 1 Condensed Consolidated Financial Statements additional information related adoption accounting pronouncement.2017 Form 10-Q 30FINANCIAL POSITION LIQUIDITY AND CAPITAL RESOURCES Three months endedMarch 31 millions)2017 2016Cash flows provided used Operating activities$2,102 $2,128Investing activities(684 1,458)Financing activities(1,794 1,219)Operating cash flows three months ended March 31 2017 reflected improved results operations resulting revenue growth improvement operating earnings offset primarily timing payments related accounts payable liabilities Cash provided operating activities reflected AbbVie voluntary contributions principal domestic defined benefit plan 150 million three months ended March 31 2017 2016 Realized excess tax benefits associated stock-based compensation totaled 26 million three months ended March 31 2017 presented within cash flows operating activities result adoption new accounting pronouncement In three months ended March 31 2016 prior adoption new accounting pronouncement realized excess tax benefits 27 million presented within cash flows financing activities See Note 1 Condensed Consolidated Financial Statements additional information regarding adoption new accounting pronouncement.Investing cash flows three months ended March 31 2017 primarily included net purchases investment securities totaling 526 million For three months ended March 31 2016 investing activities primarily included net purchases investment securities totaling 1.3 billion Cash flows investing activities three months ended March 31 2017 2016 also reflected capital expenditures.Financing cash flows included cash dividend payments 1.0 billion three months ended March 31 2017 924 million three months ended March 31 2016 The increase cash dividend payments primarily due increase dividend rate On October 28 2016 AbbVie announced board directors declared increase company's quarterly cash dividend 0.57 per share 0.64 per share beginning dividend paid February 15 2017 stockholders record January 13 2017 This reflects increase approximately 12 previous quarterly rate The timing declaration amount payment dividends within discretion board directors depend upon many factors including AbbVie financial condition earnings capital requirements operating subsidiaries covenants associated certain AbbVie debt service obligations legal requirements regulatory constraints industry practice ability access capital markets factors deemed relevant board directors.On February 16 2017 AbbVie's board directors authorized 5.0 billion increase AbbVie's existing stock repurchase program Under program company repurchased approximately 7.8 million shares 500 million open market three months ended March 31 2017 Additionally three months ended March 31 2017 AbbVie cash-settled 285 million open market purchases made end 2016 The stock repurchase authorization permits purchases AbbVie shares time time open-market private transactions management's direction depending company's cash flows net debt level market conditions The program time limit discontinued time.During three months ended March 31 2017 2016 company issued redeemed commercial paper The balance commercial paper outstanding 400 million March 31 2017 377 million December 31 2016 AbbVie may issue additional commercial paper retire commercial paper meet liquidity requirements needed.Cash equivalents impacted net favorable exchange rate changes totaling 16 million three months ended March 31 2017 net unfavorable exchange rate changes totaling 294 million three months ended March 31 2016 The unfavorable exchange rate changes 2016 primarily due devaluation AbbVie net monetary assets denominated Venezuelan bolivar While significant portion cash equivalents March 31 2017 considered reinvested indefinitely foreign subsidiaries AbbVie expect reinvestment affect liquidity capital resources If funds needed operations United States AbbVie would required accrue pay U.S income taxes repatriate funds AbbVie believes sufficient sources liquidity support assumption amount undistributed earnings March 31 2017 reinvested indefinitely.2017 Form 10-Q 31Credit RiskAbbVie monitors economic conditions creditworthiness customers government regulations funding domestically abroad AbbVie regularly communicates customers regarding status receivable balances including payment plans obtains positive confirmation validity receivables AbbVie establishes allowance accounts receivable probable collected AbbVie also monitors potential periodically utilized factoring arrangements mitigate credit risk although receivables included arrangements historically significant amount total outstanding receivables.AbbVie continues business foreign governments certain countries including Greece Portugal Italy Spain historically experienced challenges credit economic conditions Substantially AbbVie trade receivables Greece Portugal Italy Spain government health systems Outstanding net governmental receivables countries totaled 244 million March 31 2017 December 31 2016 The company also continues business foreign governments certain oil-exporting countries recently experienced deterioration economic conditions including Saudi Arabia Russia Outstanding net governmental receivables related Saudi Arabia 125 million March 31 2017 122 million December 31 2016 Outstanding net governmental receivables related Russia 110 million March 31 2017 December 31 2016 Due oil market conditions recent years liquidity issues certain countries may result delays collection receivables Global economic conditions customer-specific factors may require company periodically re-evaluate collectability receivables company could potentially incur credit losses.Currently AbbVie believe economic conditions oil-exporting countries significant impact company liquidity cash flow financial flexibility However government funding become unavailable countries significant adverse changes reimbursement practices occur AbbVie may able collect entire balance outstanding March 31 2017.Credit Facility Access Capital Credit RatingsCredit FacilityAbbVie currently 3.0 billion five-year revolving credit facility matures October 2019 The revolving credit facility enables company borrow funds unsecured basis variable interest rates contains various covenants At March 31 2017 company compliance credit facility covenants Commitment fees credit facility insignificant There amounts outstanding credit facility March 31 2017 December 31 2016.Access CapitalThe company intends fund short-term long-term financial obligations mature cash hand future cash flows operations issuing additional debt The company ability generate cash flows operations issue debt enter financing arrangements acceptable terms could adversely affected material decline demand company products solvency customers suppliers deterioration company key financial ratios credit ratings material unfavorable changes business conditions At current time company believes sufficient financial flexibility issue debt enter financing arrangements attract long-term capital acceptable terms support company growth objectives.Credit RatingsThere changes company credit ratings three months ended March 31 2017 Unfavorable changes ratings may adverse impact future financing arrangements however would affect company ability draw credit facility would result acceleration scheduled maturities company outstanding debt CRITICAL ACCOUNTING POLICIESA summary company significant accounting policies included Note 2 entitled Summary Significant Accounting Policies company Annual Report Form 10-K year ended December 31 2016 There significant changes company application critical accounting policies three months ended March 31 2017.2017 Form 10-Q 32FORWARD-LOOKING STATEMENTSSome statements quarterly report Form 10-Q may forward-looking statements purposes Private Securities Litigation Reform Act 1995 The words believe expect anticipate project similar expressions among others generally identify forward-looking statements AbbVie cautions forward-looking statements subject risks uncertainties may cause actual results differ materially indicated forward-looking statements Such risks uncertainties include limited challenges intellectual property competition products difficulties inherent research development process adverse litigation government action changes laws regulations applicable industry Additional information economic competitive governmental technological factors may affect AbbVie operations set forth Item 1A Risk Factors AbbVie Annual Report Form 10-K year ended December 31 2016 filed Securities Exchange Commission AbbVie notes factors investors permitted Private Securities Litigation Reform Act 1995 AbbVie undertakes obligation release publicly revisions forward-looking statements result subsequent events developments except required law.ITEM 3 QUANTITATIVE AND QUALITATIVE